Vincerx Pharma Terminates Sales Agreement with Leerink Partners LLC and Holds Special Meeting of Stockholders

On January 10, 2025, Vincerx Pharma, Inc. announced the termination of its Sales Agreement with Leerink Partners LLC, which was initially dated March 29, 2024. This agreement allowed the company to offer and sell shares of its common stock with an aggregate offering price of up to $50,000,000 through “at-the-market” offerings as defined in Rule 415(a)(4) of the Securities Act of 1933. Following the termination, Vincerx Pharma had sold approximately $2,474,596.53 of its common stock under the Sales Agreement based on the ATM Prospectus.

Furthermore, on January 16, 2025, the company held a Special Meeting of Stockholders where an important proposal was discussed and approved. Stockholders voted to amend the Second Amended and Restated Certificate of Incorporation to implement a reverse stock split of the issued shares of Vincerx Pharma’s common stock, with a ratio ranging between 1 share for 10 shares to 1 share for 20 shares. The exact ratio to be implemented will be disclosed in a public announcement, as outlined in the proxy statement for the Special Meeting.

The final voting results from the Special Meeting were as follows:
– For: 19,086,094 shares
– Against: 2,371,869 shares
– Abstain: 230,463 shares

No further details regarding the Special Meeting were provided in the SEC filing. Raquel E. Izumi, the Acting Chief Executive Officer of Vincerx Pharma, signed the report on behalf of the company as of January 16, 2025.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Vincerx Pharma’s 8K filing here.

Vincerx Pharma Company Profile

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.